NVCT

Business Context and Reporting Period

Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. The company has no products approved for commercial sale and has not generated any revenue to date. This summary covers the fiscal year ended December 31, 2024, as reported in the Form 10-K filed on February 25, 2025.

The company's pipeline consists of two primary product candidates:

• NXP800: A GCN2 kinase activator in Phase 1b clinical trials for platinum-resistant, ARID1a-mutated ovarian carcinoma and cholangiocarcinoma. It holds FDA Fast Track and Orphan Drug Designations.
• NXP900: A SRC and YES1 kinase inhibitor in Phase 1a clinical trials for solid tumors.

Key Financial Metrics

Expense Breakdown (2024): Research and Development (R&D) expenses were $12.9 million, and General and Administrative (G&A) expenses were $6.9 million. Stock-based compensation totaled $4.9 million ($3.0M in R&D, $1.9M in G&A).

Material Changes vs. Prior Period

• Reduced Operating Loss: The net loss decreased by approximately $3.3 million (14.7%) compared to 2023, driven primarily by a $2.5 million reduction in R&D expenses.
• R&D Efficiency: R&D expenses declined from $15.4 million in 2023 to $12.9 million in 2024. This decrease was largely due to a reduction in manufacturing costs (from $3.5M to $1.5M) and the absence of a $1.0 million one-time license fee payment recorded in 2023.
• G&A Reduction: G&A expenses decreased by $0.6 million, primarily due to lower insurance costs and slightly reduced employee compensation.
• Capital Raising: In 2024, the company raised approximately $11.7 million in net proceeds through its At-the-Market (ATM) offering program. In early 2025 (subsequent to the reporting period), the company completed a public offering raising approximately $13.9 million in net proceeds.

Outlook, Risks, and Contingencies

Liquidity and Capital Resources: As of December 31, 2024, the company held $18.5 million in cash. Management believes this, combined with proceeds from the February 2025 offering, is sufficient to fund operations for at least 12 months. However, the company expects to incur continued losses and will require substantial additional capital to advance clinical trials and achieve commercialization.

Key Risks:

• Clinical Development: Success depends on the safety and efficacy of NXP800 and NXP900 in ongoing Phase 1 trials. Preliminary data announced in 2024 is not predictive of future results.
• Regulatory Approval: No products are approved; regulatory approval is uncertain and may be delayed or denied.
• Third-Party Reliance: The company relies on third-party manufacturers for drug substance and product, creating supply chain risks.
• Intellectual Property: The company relies on licensed patents (expiring 2034-2037) and faces risks of infringement claims or failure to maintain protection.

Contingencies: The company has significant contingent milestone obligations under license agreements with the CRT Pioneer Fund (up to $204.5 million total) and the University of Edinburgh (up to $329 million total), payable upon regulatory and commercial milestones.

Investor Verification Checklist

• Verify the sufficiency of the $18.5 million cash balance plus the $13.9 million subsequent offering proceeds against the projected burn rate for the next 12-18 months.
• Review the specific preliminary safety and efficacy data for NXP800 announced in March and November 2024 to assess clinical progress.
• Confirm the status of the Phase 1b expansion cohort for NXP800 and the Phase 1a dose-escalation for NXP900.
• Assess the terms of the license agreements with the University of Edinburgh and CRT Pioneer Fund, specifically the milestone triggers and royalty rates.
• Monitor the company's ability to raise further capital given the dilution from recent equity offerings and the lack of revenue.